Precision BioSciences priced an underwritten public offering of 10,235,077 shares of common stock at $7.75 per share and pre-funded warrants to purchase up to 5,893,964 additional shares. Gross proceeds are expected to be approximately $125 million, with net proceeds estimated at roughly $116.5 million after deducting underwriting discounts and offering expenses. The company intends to use the funds for research and development of its PBGENE-HBV and PBGENE-DMD programs, as well as working capital and general corporate purposes. The transaction closed on November 6, 2026.
